Vaxcyte, Inc. (PCVX) earnings
PCVX earnings moved a median of -0.17% by the close. Quarterly and annual PCVX reports and results, each read against the price at its own news timestamp. Back to the PCVX overview →
21 measured PCVX earnings events.
Where these PCVX earnings landedvs 21 measured PCVX earnings reactions
| Middle 50% of PCVX earnings reactions | -4.50% to +3.76% |
|---|---|
| Median reaction (to close) | -0.17% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 PCVX earnings events with a measured close landed between -4.50% and +3.76%; 43% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Vaxcyte, Inc. For: Jun 30 | SEC filing · Form 10-Q | +3.45% | +6.74% | |
| Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +3.45% | +6.74% | |
| Form 10-Q Vaxcyte, Inc. For: Mar 31 | SEC filing · Form 10-Q | -6.04% | -6.42% | |
| Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | -6.04% | -6.42% | |
| Form 10-K Vaxcyte, Inc. For: Dec 31 | SEC filing · Form 10-K | +6.91% | +9.12% | |
| Form 10-Q Vaxcyte, Inc. For: Sep 30 | SEC filing · Form 10-Q | +1.12% | -1.47% | |
| Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study | Press release | +1.12% | -1.47% | |
| Form 10-Q Vaxcyte, Inc. For: Jun 30 | SEC filing · Form 10-Q | +2.16% | -0.17% | |
| Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) | Press release | +2.16% | -0.17% | |
| Form 10-Q Vaxcyte, Inc. For: Mar 31 | SEC filing · Form 10-Q | -0.07% | +3.76% | |
| Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | -0.07% | +3.76% | |
| Form 10-K Vaxcyte, Inc. For: Dec 31 | SEC filing · Form 10-K | -2.62% | -5.15% | |
| Form 10-Q Vaxcyte, Inc. For: Sep 30 | SEC filing · Form 10-Q | -6.17% | -9.17% | |
| Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | -6.17% | -9.17% | |
| Form 10-Q Vaxcyte, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.13% | -4.42% | |
| Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -1.13% | -4.42% | |
| Form 10-Q Vaxcyte, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.40% | +0.88% | |
| Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +1.40% | +0.88% | |
| Form 10-K Vaxcyte, Inc. For: Dec 31 | SEC filing · Form 10-K | +3.87% | -4.50% | |
| Form 10-Q Vaxcyte, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.95% | +4.69% | |
| Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update | Press release | +0.95% | +4.69% |
Keep exploring
More PCVX: analyst actions → · SEC filings → · PCVX overview →